Notwithstanding these important caveats, the recent molecular findings provide a tantalizing possibility that brain-enriched isoforms of CACNA1C - and other VGCCs - could be preferentially targeted, allowing therapeutic agents for psychiatric disorders with greater central potency and fewer peripheral side-effects (Harrison et al., 2020b; Hall and Tunbridge, 2021). Here, CACNA1C is linked to psychiatric disorder.